Tuberkulose-Behandlung
© Dr. Jan Heyckendorf/FZ Borstel

Successful Translation

There are considerable translational successes at the DZIF: an overview of our flagship projects

The DZIF's goal is to conduct translational infection research, enabling research results to be transferred more quickly from the laboratory to patients. To achieve this, doctors and scientists work closely together, sharing their results and experiences. 

Translational projects in the late preclinical and early clinical phases may be designated as "DZIF flagship projects." These projects receive special support and advice from the Product Development Unit.

For detailed information on our DZIF flagship projects, please click on the respective picture:

Microscopic image of virus-like particles of the hepatitis E virus, shown as bright, dot-like structures on a dark background. Above it is the title "Antibodies against the hepatitis E virus – HEVbnAb as a new treatment option for chronic and acute HEV infections" with the DZIF logo.

This DZIF flagship project involves the further development of broadly neutralizing antibodies from the serum of recovered patients as a specific treatment option for chronic and acute hepatitis E virus infections.
Learn more

 

© CDC/PHIL#5605
Structural illustration of an antibody (yellow) bound to a bacterial protein (blue) from Pseudomonas aeruginosa, shown in two perspectives. Text: “Antibodies against multidrug-resistant pathogens – A new treatment option against Pseudomonas aeruginosa.”

The PANTIPA project is developing highly effective antibodies from patients to be used clinically against Pseudomonas aeruginosa infections.
Learn more

 

© CSSB/Biao Yuan
Successful translation at the DZIF: New drug substance BTZ-043 for tuberculosis.

Since 2014, DZIF scientists are developing a promising antibiotic for tuberculosis, which has also proven to be effective against multidrug-resistant pathogens in preclinical tests.
Learn more

 

© CDC/James Archer
Agent against hospital pathogens: Click on the picture to learn more about the project.

Our scientists at the Universities of Tübingen and Munich are developing an active agent that will be used against the dreaded pathogen Staphylococcus aureus.
Learn more

 

© NIAID
Development of a MERS vaccination: Click on the picture to learn more about the project.

A promising vaccine candidate against the MERS coronavirus has been researched up to clinical phase I at the DZIF and is now being further developed.
Learn more

 

© Drosten/Uniklinik Bonn
Successful translation at the DZIF: Corallopyronin A is a promising candidate against worm infections.

Already in 2009 Prof. Achim Hörauf and his team at the University Hospital Bonn discovered that the natural substance Corallopyronin A is effective against worm infections.
Learn more

 

© Achim Hörauf
Vaccine against Epstein-Barr virus: Click on the picture to learn more about the project.

We have been researching the Epstein-Barr virus at the DZIF for many years and now a promising vaccine candidate is passing from the laboratory to quality-assured production.
Learn more

 

© Georg Hornkamm/Helmholtz Zentrum München
Successful translation at the DZIF: TherVacB offers a new therapeutic approach to cure chronic hepatitis B..

As a therapeutic vaccine against hepatitis B, TherVacB is expected to be tested in a clinical trial starting in mid-2021.
Learn more

 

© CDC/Erskine Palmer
Successful translation at the DZIF: Stephan Urban has achieved great success in the treatment of hepatitis D.

At the Heidelberg University Hospital, DZIF professor Stephan Urban and his team developed the first drug for hepatitis D.
Learn more

 

© Universitätsklinikum Heidelberg